Emyria
Emyria (ASX:EMD) is a Perth-based, ASX-listed biotech developing treatments for mental health and neurological conditions, including psychedelic-assisted therapies for PTSD and treatment-resistant depression. It runs its own clinical service subsidiaries to gather real-world patient data alongside its drug development programmes.
- Sector
- Clinical-stage biotech (mental health, neurological)
- Founded
- 2018
- Headquarters
- Leederville
- Status
- ASX-listed (ASX: EMD)
Sources: businessnewsaustralia.com, stockanalysis.com
1person interviewed
1episode across 1 show
The team on Day One
Hear from the team
Spot something wrong? Suggest a correction Updated 25 September 2026